Join us for an engaging educational symposium designed for all nurses who care for skin cancer patients.

Hosted by Melanoma Institute Australia, this symposium brings together leading multidisciplinary experts to explore the latest developments in melanoma and non-melanoma skin cancer (NMSC) management to ultimately improve your patient care.

Gain valuable insights into:

A comprehensive melanoma overview
The latest topical treatments for lentigo maligna and NMSC
The role of genetic testing in melanoma
Early assessment and management of rare immunotherapy toxicities
Neoadjuvant melanoma treatment from multidisciplinary perspectives
Multidisciplinary case study discussion
Managing complex head and neck skin cancers
Understanding mucosal melanoma
Available support services for patients and healthcare providers
An update on the National Melanoma Nursing Program

The day includes opportunities to engage with experts during Q&A sessions, an interactive quiz and opportunities to network with your colleagues.

Please note that the program is subject to change and will be released closer to the date.

Date: Thursday 8 May 2025, 8:30am to 3:30pm (Registration will open at 8am with presentations commencing at 8:30am sharp)

Venue: Melanoma Institute Australia, The Poche Centre, 40 Rocklands Rd, Wollstonecraft NSW 2065

Cost: $95 (inc GST). Ticket prices includes morning tea, lunch and afternoon tea.

Parking: Limited free street parking may be available. Discounted paid parking ($10) will be available onsite at The Poche Centre (entry via Rocklands Rd). Public transport is encouraged.

CPD: A Certificate of Attendance will be given after the event.

RSVP: By 24 April 2025. Note that ticket numbers are strictly limited and as this is a popular event, tickets are likely to be sold out before then.

Safety at our event: Please follow COVID-safe practices when attending our event and stay home if you are feeling unwell. If you can no longer attend due to COVID-19, please contact us.

MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb and HEINE.